Eur Rev Med Pharmacol Sci 2023; 27 (17): 8212-8217
DOI: 10.26355/eurrev_202309_33581

Effect of Ezetimibe combined with Simvastatin in the treatment of coronary heart disease: a retrospective analysis

B. Li, Y. Li, W.-Z. Peng, Y.-Q. Liu, Z.-S. Xu, J.-K. Wen

Department of Biochemistry and Molecular Biology, The Key Laboratory of Neural and Vascular Biology, China Administration of Education, Hebei Medical University, Shijiazhuang, Hebei Province, China. xuzeshengcz@163.com


OBJECTIVE: The aim of this study was to explore the effect of Ezetimibe combined with Simvastatin in the treatment of coronary heart disease (CHD).

PATIENTS AND METHODS: Clinical data of 101 patients with CHD, admitted to our hospital from February 2022 to May 2023, were retrospectively analyzed. Among them, 49 patients received Simvastatin (Simvastatin group), and 52 patients received Simvastatin+Ezetimibe (Simvastatin+Ezetimibe group). Levels of blood lipid indicators, inflammatory factors, cardiac function indicators, and incidences of major adverse cardiovascular events (MACE) between the two groups were compared before and after the treatment.

RESULTS: After the treatment, high-density lipoprotein cholesterol (HDL-C), cardiac index (CI), and left ventricular ejection fraction (LVEF) in both groups were higher than those before the treatment, and overall higher in the Simvastatin+Ezetimibe group. Levels of low-density lipoprotein-cholesterol (LDL-C), triglycerides (TG), total cholesterol (TC), monocyte chemoattractant protein-1 (MCP-1), chemokine ligand 19 (CCL19), high sensitivity C-reactive protein (hs-CRP), cardiac output (CO) in the two groups were lower than before the treatment. These indexes were significantly lower in the Simvastatin+Ezetimibe group (p<0.05) compared to the Simvastatin group. During the treatment, the incidence of MACE in the Simvastatin+Ezetimibe group (3.85%) was significantly lower than that in the Simvastatin group (16.33%) (p<0.05).

CONCLUSIONS: Compared with Simvastatin alone, a combination of Ezetimibe and Simvastatin can more effectively regulate the level of blood lipids, reduce the inflammatory reaction in the body, improve heart function, and lower the risk of MACE.

Free PDF Download

To cite this article

B. Li, Y. Li, W.-Z. Peng, Y.-Q. Liu, Z.-S. Xu, J.-K. Wen
Effect of Ezetimibe combined with Simvastatin in the treatment of coronary heart disease: a retrospective analysis

Eur Rev Med Pharmacol Sci
Year: 2023
Vol. 27 - N. 17
Pages: 8212-8217
DOI: 10.26355/eurrev_202309_33581